Kaempferol enhances cisplantin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc

Luo, Haitao; Daddysman, Matthew K.; Rankin, Gary O.; Bing-Hua Jiang; Chen, Yi C.
January 2010
Cancer Cell International;2010, Vol. 10, p16
Academic Journal
Background: Ovarian cancer is one of the most significant malignancies in the western world. Studies showed that Ovarian cancers tend to grow resistance to cisplatin treatment. Therefore, new approaches are needed in ovarian cancer treatment. Kaempferol is a dietary flavonoid that is widely distributed in fruits and vegetables, and epidemiology studies have revealed a protective effect of kaempferol against ovarian cancer risk. Our early studies also found that kaempferol is effective in reducing vascular endothelial growth factor (VEGF) expression in ovarian cancer cells. In this study, we investigated kaempferol's effects on sensitizing ovarian cancer cell growth in response to cisplatin treatment. Results: Ten chemicals were screened for sensitizing OVCAR-3 ovarian cancer cell growth in response to cisplatin treatment. For kaempferol, which shows a significant synergistic interaction with cisplatin, expression of ABCC1, ABCC5, ABCC6, NFkB1, cMyc, and CDKN1A genes was further examined. For cisplatin/kaempferol treatments on OVCAR-3 cancer cells, the mRNA levels of ABCC1, ABCC5, and NFkB1 did not change. However, significant inhibition of ABCC6 and cMyc mRNA levels was observed for the cisplatin/kaempferol combined treatment. The CDKN1A mRNA levels were significantly up-regulated by cisplatin/kaempferol treatment. A plot of CDKN1A mRNA levels against that of cMyc gene further revealed a reverse, linear relationship, proving cMyc's regulation on CDKN1A gene expressions. Our work found that kaempferol works synergistically with cisplatin in inhibiting ovarian cancer cell viability, and their inhibition on cell viabilities was induced through inhibiting ABCC6 and cMyc gene transcription. Apoptosis assay showed the addition of 20 μM kaempferol to the cisplatin treatment induces the apoptosis of the cancer cells. Conclusions: Kaempferol enhances the effect of cisplatin through down regulation of cMyc in promoting apoptosis of ovarian cancer cells. As a dietary component, kaempferol sensitizes ovarian cancer cells to cisplatin treatment and deserves further studies for possible applications in chemotherapy of ovarian cancers.


Related Articles

  • Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer. Hiroshi Kawaguchi; Yoshito Terai; Akiko Tanabe; Hiroshi Sasaki; Masaaki Takai; Satoe Fujiwara; Keisuke Ashihara; Yoshimichi Tanaka; Tomohito Tanaka; Satoshi Tsunetoh; Masanori Kanemura; Masahide Ohmichi // Journal of Ovarian Research;2014, Vol. 7 Issue 1, p1 

    Background Gemcitabine (2', 2'-difluorodeoxycytidine) is one of many nonplatinum drugs that exhibit activity in recurrent, platinum-resistant ovarian cancer. However, the molecular mechanisms by which Gemcitabine treatment inhibits the proliferation of platinum-resistant ovarian cancer cells...

  • Effects of SC-560 in Combination with Cisplatin or Taxol on Angiogenesis in Human Ovarian Cancer Xenografts. Wei Li; Liang Wan; Ling-Yun Zhai; Jane Wang // International Journal of Molecular Sciences;Oct2014, Vol. 15 Issue 10, p19265 

    This study was designed to evaluate the effect of cyclooxygenase-1 (COX-1) inhibitor, SC-560, combined with cisplatin or taxol, on angiogenesis in human ovarian cancer xenografts. Mice were treated with intraperitoneal (i.p.) injections of SC-560 6 mg/kg/day, i.p. injections of cisplatin 3 mg/kg...

  • Tumor immune surveillance and ovarian cancer. Kandalaft, Lana; Motz, Gregory; Duraiswamy, Jaikumar; Coukos, George // Cancer & Metastasis Reviews;Mar2011, Vol. 30 Issue 1, p141 

    In the past few years, cancer immunotherapies have produced promising results. Although traditionally considered unresponsive to immune therapy, increasing evidence indicates that ovarian cancers are, in fact, immunogenic tumors. This evidence comes from diverse epidemiologic and clinical data...

  • CD31 microvessel density a prognostic factor in ovarian cancer. Secord, Angeles Alvarez // Hem/Onc Today;5/10/2008, Vol. 9 Issue 8, p23 

    The article reports that increased vascular endothelial growth factor (VEGF) in the tissue is related to increased development of blood vessels and low thrombospondin-1 levels, but not associated with outliving ovarian cancer to patients treated with bevacizumab. The study was presented by...

  • Overexpression of Her-2/neu in Epithelial Ovarian Carcinoma Induces Vascular Endothelial Growth Factor C by Activating NF-κB: Implications for Malignant Ascites Formation and Tumor Lymphangiogenesis. Chang-Yao Hsieh; Chi-An Chen; Chia-Hung Chou; Kuo-Pao Lai; Yung-Ming Jeng; Min-Liang Kuo; Lin-Hung Wei // Journal of Biomedical Science;Mar/Apr2004, Vol. 11 Issue 2, p249 

    Vascular endothelial growth factor C (VEGF-C) is an important growth factor that governs lymphatic spread and the development of intraperitoneal tumors associated with epithelial ovarian cancer; however, its regulation is not yet understood. Overexpression of Her-2/neu is related to poor...

  • VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Gavalas, N G; Tsiatas, M; Tsitsilonis, O; Politi, E; Ioannou, K; Ziogas, A C; Rodolakis, A; Vlahos, G; Thomakos, N; Haidopoulos, D; Terpos, E; Antsaklis, A; Dimopoulos, M A; Bamias, A // British Journal of Cancer;11/20/2012, Vol. 107 Issue 11, p1869 

    Background:Vascular endothelial growth factor action in tumour angiogenesis is well characterised; nevertheless, it functions as a key element in the promotion of the immune system's evasion by tumours. We sought to investigate the possible direct effect of VEGF on T-cell activation and through...

  • The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Huang, Ke-Jin; Sui, Li-Hua // Medical Oncology;Mar2012, Vol. 29 Issue 1, p318 

    We investigated the correlation of vascular endothelial growth factor C, matrix metalloproteinase-2, E-cadherin to explore mechanisms of vascular endothelial growth factor C in the metastasis of ovarian cancer and the relationship of prognosis. We applied immunohistochemistry to investigate the...

  • Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. Aravantinos, Gerasimos; Pectasides, Dimitrios // Journal of Ovarian Research;2014, Vol. 7 Issue 1, p1 

    As increased angiogenesis has been linked with the progression of ovarian cancer, a number of anti-angiogenic agents have been investigated, or are currently in development, as potential treatment options for patients with advanced disease. Bevacizumab, a recombinant monoclonal antibody against...

  • Targeting Angiogenesis in Ovarian Carcinoma. Mendiola, Marta; Barriuso, Jorge; Hardisson, David // Current Cancer Therapy Reviews;2009, Vol. 5 Issue 3, p188 

    Ovarian carcinoma is the leading cause of gynecological cancer-related mortality. Cytoreductive surgery followed by combination chemotherapy including paclitaxel and a platinum compound usually results in complete remission in approximately 70% of patients. Despite this, the majority of patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics